The ethical boundaries of patient and advocate influence on DSM-5

Harvard Review of Psychiatry

Volumn 21, Issue 6, 2013, Pages 334-344

  Johnson, Rebecca A ^a,b   Barrett, Marna S ^c   Sisti, Dominic A ^b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Scattergood Program for Applied Ethics in Behavioral Healthcare   (Canada)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Diagnostic and statistical manual of mental disorders; Ethics; Mental disorders; Patient advocacy; Social stigma

Indexed keywords

ARTICLE; ASPERGER SYNDROME; AUTISM; BENEFICENCE; CONFLICT MANAGEMENT; CONSUMER ADVOCACY; DRUG INDUSTRY; DSM-5; FUNDING; GENDER DYSPHORIA; HEALTH CARE FINANCING; MEDICAL ETHICS; MEDICAL RESEARCH; MEDICAL SOCIETY; MOOD DISORDER; PATIENT ADVOCACY; PEDOPHILIA; PERVASIVE DEVELOPMENTAL DISORDER NOT OTHERWISE SPECIFIED; PRIORITY JOURNAL; PSYCHIATRIC DIAGNOSIS; PSYCHOSEXUAL DISORDER; PSYCHOSIS; REIMBURSEMENT; SCHIZOPHRENIA; SOCIAL STIGMA; SPECIAL EDUCATION; SUBSTANCE ABUSE; SURVIVOR; TEMPER DYSREGULATION DISORDER;

DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; HUMANS; MENTAL DISORDERS; PATIENT ADVOCACY; RISK;

EID: 84896692952     PISSN: 10673229     EISSN: 14657309     Source Type: Journal    
DOI: 10.1097/HRP.0000000000000010     Document Type: Article

References (75)

1. Brim RL, Pearson SD. The use and reporting of patient-reported outcomes in phase III breast cancer trials. Clin Trials 2013;10:243-9.
2. Barry MJ, Edgman-Levitan S. Shared decision making - the pinnacle of patient-centered care. N Engl J Med 2012;366:780-1.
3. Garber AM. How the Patient-Centered Outcomes Research Institute can best influence real-world health care decision making. Health Aff 2011;30:2243-51.
4. Regier DA, Kuhl EA, Kupfer DJ, et al. Patient involvement in the development of DSM V. Psychiatr Serv 2010;73:308-10.
5. Epstein S. Impure science: AIDS, activism, and the politics of knowledge. Berkeley: University of California Press, 1996.
6. Dresser R. When science offers salvation: patient advocacy and research ethics. New York: Oxford University Press, 2001.
7. Schwartz LM, Woloshin S, Fowler FJ Jr, Welch HG. Enthusiasm for cancer screening in the United States. JAMA 2004;291:71-8.
8. Yarborough M, Sharp RR. Bioethics consultation and patient advocacy organizations: expanding the dialogue about professional conflicts of interest. Camb Q Healthc Ethics 2006;16:74-81.
9. Szasz T. The myth of mental illness: foundations of a theory of personal conduct. New York: Harper & Row, 1974.
10. Mayes R, Horwitz AV. DSM-III and the revolution in classification of mental illness. J Hist Behav Sci 2005;41:249-67.
11. Tomes N. The patient as a policy factor: a historical case study of the consumer/survivor movement in mental health. Health Aff 2006;25:720-9.
12. Anspach RR. From stigma to identity politics: political activism among the physically disabled and former mental patients. Soc Sci Med 1979;13A:765-73.
13. Dixon L, Goldman H, Hirad A. State policy and funding of services to families of adults with serious and persistent mental illness. Psychiatr Serv 1999;50:551-3.
14. National Alliance on Mental Illness. Federal funding for mental illness research. 2003. http://www.nami.org/Template.cfm?Section=Issue- Spotlights&template=/ContentManagement/ContentDisplay.cfm&ContentID=8560
15. Autism Speaks. Why do federal dollars go down when autism is on the rise? 2012. http://www.autismspeaks.org/advocacy/advocacy-news/autism-speaks- congress-why-do-federal-dollars-autism-go-down-when-prevalence.
16. Brain and Behavior Research Foundation. Our history. 2013. http://bbrfoundation.org/about/our-history
17. Best RK. Disease politics and medical research funding: three ways advocacy shapes policy. Am Sociol Rev 2012;77:780-803.
18. Rothman SM. Health advocacy organizations and evidence-based medicine. JAMA 2011;305:2569-70.
19. Patient-Centered Outcomes Research Institute. Public comments. http://www.pcori.org/research-we-support/priorities-agenda-draft/ public-comments/
20. Singh J, Illes J, Lazzeroni L, Hallmayer J. Trends in US autism research funding. J Autism Dev Disord 2009;39:788-95.
21. National Conference of State Legislators. Insurance coverage for autism. 2012. http://www.ncsl.org/issues-research/health/autism-and-insurance-coverage- state-laws.aspx
22. Autism Speaks. Return of organization exempt from income tax (Internal Revenue Service Form 990). 2011. http://www.autismspeaks.org/sites/default/ files/documents/2011-tax-form-990.pdf
23. American Psychiatric Association. Meet us: neurodevelop-mental disorders. 2012. http://www.dsm5.org/MeetUs/Pages/Neurodevelopmental%20Disorders.aspx
24. Combating Autism Act of 2006. Pub. L. No. 109-416, §843. 120 Stat. 2821 (2006).
25. McPartland JC, Reichow B, Volkmar FR. Sensitivity and specificity of proposed DSM-5 diagnostic criteria for Autism Spectrum Disorder. J Am Acad Child Psy 2012;51:368-83.
26. Autism Speaks. Autism Speaks funds research on impact of DSM-5 on autism diagnosis. 2012. http://www.autismspeaks.org/science/science-news/autism-speaks- funds-research-impact-dsm-5-autism-diagnosis
27. American Psychiatric Association. American Psychiatric Association Board of Trustees Approves DSM-5 [News release]. 1 December 2012.
28. Singer E. Diagnosis: redefining autism. Nature 2012;491:S12-13
29. National Alliance for Mental Illness. Who is NAMI? 2009. http://namivirginia.org/assets/pdfs/NAMI%20Fact%20Sheet%20-%20update%20address. pdf
30. National Alliance on Mental Illness. Return of organization exempt from income tax (Internal Revenue Service Form 990). 2011.
31. Jeste DV. Partnership with advocates strengthens us. Psychiatric News 2012;2 Nov. http://psychnews.psychiatryonline.org/newsarticle.aspx?articleid= 1387814
32. National Alliance on Mental Illness. NAMI comments on the APA's draft DSM-V. n.d. http://www.nami.org/Content/ContentGroups/Policy/Issues-Spotlights/ DSM5/NAMI-Comments-on-APAs-Draft-DSM-V.htm
33. Link BG, Phelan J, Bresnahan M, Stueve A, Pescosolido BA. Public conceptions of mental illness: labels, causes, dangerousness, and social distance. Am J Public Health 1999;89:1328-33.
34. Clark RE, Ricketts SK, McHugo GJ. Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatr Serv 1999;50:641-8.
35. Axelson DA, Birnaher B, Findling RL, et al. Concerns regarding the inclusion of temper dysregulation disorder with dysphoria in the Diagnostic and Statistical Manual of Mental Disorders, fifth edition. J Clin Psychiatry 2011;72:1257-62.
36. Miller TJ, McGlashan TH, Rosen JL, et al. Prodromal assessment with the structured interview for prodromal syndromes and the scale of prodromal symptoms: predictive validity, interrater reliability, and training to reliability. Schizophr Bull 2003;29:703-15.
37. Cannon TD, Cadenhead K, Cornblatt B, et al. Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiat 2008;65:28-37.
38. National Alliance on Mental Illness. NAMI comments on the APA's draft revision of the DSM-V: proposed new diagnosis: psychosis risk syndrome. n.d. http://www.nami.org/Content/ContentGroups/Policy/Issues-Spotlights/DSM5/ Risk-Syndrome-Paper-4-13-2010.pdf
39. Corcoran CM, First MB, Cornblatt B. The psychosis risk syndrome and its proposed inclusion in the DSM-V: a risk-benefit analysis. Schizophr Res 2010;120:16-22.
40. National Alliance on Mental Illness. Return of organization exempt from income tax (Internal Revenue Service Form 990). 2010.
41. National Alliance on Mental Illness. First episode: psychosis, results from a 2011 NAMI survey. 2011. http://www.nami.org/FirstEpisode/ firstepisodesurvey.pdf
42. Compton MT, Goulding SM, Ramsay CE, Addington J, Corcoran C, Walker EF. Early detection and intervention for psychosis: perspectives from North America. Clin Neuropsychiatry 2008;5:263-72.
43. Welsh P, Tiffin PA. Assessing adolescent preference in the treatment of first-episode psychosis and psychosis risk. Early Interv Psychiatry 2013, doi: 10.1111/eip.12077 [Epub ahead of print].
44. Correll CU, Hauser M, Auther AM, Cornblatt BA. Research in people with the psychosis risk syndrome: a review of current evidence and future directions. J Child Psychol Psychiatry 2010;51:390-431.
45. Harris G. Drug makers are advocacy group's biggest donors. NY Times 2009;23 Oct: A23.
46. Maxmen A. Psychosis risk syndrome excluded from DSM-5. Nature News 2012;9 May. http://www.nature.com/news/psychosis-risk-syndrome-excluded-from-dsm-5-1. 10610
47. Regier DA, Narrow WE, Clarke DE, et al. DSM-5 field trials in the United States and Canada, part II: test-retest reliability of selected categorical diagnoses. Am J Psychiatry 2013;170:59-70.
48. Tsuang MT, Van Os J, Tandon R, et al. Attenuated psychosis syndrome in DSM-5. Schizophr Res 2013;14 Jun. doi: 10.1016/j.schres.2013.05.004 [Epub ahead of print].
49. Schizophrenia Research Forum. Live discussion: is the risk syndrome for psychosis risky business? 4 Oct 2009. http://www.schizophreniaforum.org/for/ live/transcript.asp?liveID=68.
50. B4U-ACT. About us. 2012. http://www.b4uact.org/about.htm
51. B4U-ACT. Return of organization exempt from income tax (Internal Revenue Service Form 990). 2008.
52. B4U-ACT. B4U-ACT participates in conference call with DSM revision officials [Press release]. 12 Jun 2010. http://www.b4uact.org/news/20100612.htm
53. Rossomando J. Conference aims to normalized pedophilia. Daily Caller 2011;15 Aug. http://dailycaller.com/2011/08/15/conference-aims-to-normalize- pedophilia/
54. Blanchard R, Lykins AD, Wherrett D, et al. Pedophilia, hebephilia, and the DSM-V. Arch Sex Behav 2009;38:335-50.
55. Kramer R. APA guidelines ignored in the development of diagnostic criteria for pedophebephilia. Arch Sex Behav 2011;40:233-5.
56. Fabian JM. Diagnosing and litigating hebephilia in sexually violent predator civil commitment hearings. J Am Acad Psych 2011;39:496-505.
57. Sorrentino R. Forensic implications of DSM-V's Pedohebephilia. Paper presented at B4U-ACT Scientific Symposium on Pedophilia and the DSM, Baltimore, MD, 17 Aug 2011.
58. Frances A, First M. Hebephilia is not a mental disorder in DSM-IV-TR and should not become one in DSM-5. J Am Acad Psychiatry 2011;39:78-85.
59. Franklin K. APA rejects 'hebephilia,' last standing of three novel sexual disorders. 2 Dec 2012. http://forensicpsychologist.blogspot.com/2012/12/apa- rejects-hebephilia-last-of-three.html
60. Link BG, Yang LH, Phelan JC, Collins PY. Measuring mental illness stigma. Schizophr Bull 2004;30:511-41.
61. Watson AC, Ottati V, Corrigan P. From whence comes mental illness stigma? Int J Soc Psychiatry 2003;49:142-57.
62. Collins H, Evans R. Rethinking expertise. Chicago: University of Chicago Press, 2007.
63. National Alliance on Mental Illness. NAMI encourages DSM-5 discussion [Press release]. 12 Feb 2010. http://www.nami.org/Template.cfm?Section=press- release-archive&template=/content-management/contentdisplay. cfm&ContentID=94392&title=NAMI%20Encourages%20DSM-5%20Discussion
64. Wakefield JC. The concept of mental disorder: diagnostic implications of harmful dysfunction analysis. World Psychiatry 2007;6:149-56.
65. Lord C, Jones RM. Annual research review: re-thinking the classification of Autism Spectrum Disorders. J Child Psychol Psyc 2012;53:490-509.
66. Sharma S, Woolfson LM, Hunter SC. Confusion and inconsistency in diagnosis of Asperger syndrome: a review of studies from 1981 to 2010. Autism 2011;16:465-86.
67. Frank RG, Glied SA. Better but not well: mental health policy in the United States since 1950. Baltimore, MD: John Hopkins University Press, 2006.
68. Schlesinger M. A loss of faith: the sources of reduced political legitimacy for the American medical profession. Milbank Q 2002;80:185-235.
69. Brown P, Zavestoski S, McCormick S, Mayer B, Morello-Frosch R, Altman RG. Embodied health movements: new approaches to social movements in health. Sociol Health Ill 2004;26:50-80.
70. Cosgrove C, Krimsky S. Acomparison of DSM-IV and DSM-5 panel members' financial associations with industry: a pernicious problem persists. PLOS Med 2012;9:e1001190.
71. Moynihan RN, Cooke GPE, Doust JA, Bero L, Hill S, Glasziou PP. Expanding disease definitions in guidelines and expert panel ties to industry: a cross-sectional study of common conditions in the United States. PLOS Med 2013. http://www.plosmedicine.org/article/info%3Adoi%2F10.1371%2Fjournal.pmed.1001500
72. Rothman SM, Raveis VH, Friedman A, Rothman DJ. Health advocacy organizations and the pharmaceutical industry: an analysis of disclosure practices. Am J Public Health 2011;101: 602-9.
73. Hansen HB, Donaldson Z, Link BG, et al. Independent review of social and population variation in mental health could improve diagnosis in DSM revisions. Health Aff 2013;32:1-10.
74. Johnson RA. Pure science and impure influences: the DSM at a social, legal, and scientific crossroads. DePaul J Health Care L (forthcoming).
75. American Psychiatric Association. APA modifies DSM naming convention to reflect publication changes [News release]. 9 Mar 2010. http://www.dsm5.org/ Documents/DSM-Name-Change.pdf